These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 33753421)

  • 41. Comparison of Seroconversion in Children and Adults With Mild COVID-19.
    Toh ZQ; Anderson J; Mazarakis N; Neeland M; Higgins RA; Rautenbacher K; Dohle K; Nguyen J; Overmars I; Donato C; Sarkar S; Clifford V; Daley A; Nicholson S; Mordant FL; Subbarao K; Burgner DP; Curtis N; Bines JE; McNab S; Steer AC; Mulholland K; Tosif S; Crawford NW; Pellicci DG; Do LAH; Licciardi PV
    JAMA Netw Open; 2022 Mar; 5(3):e221313. PubMed ID: 35262717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre.
    Chukwu CA; Mahmood K; Elmakki S; Gorton J; Kalra PA; Poulikakos D; Middleton R
    PLoS One; 2022; 17(3):e0265130. PubMed ID: 35271655
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy.
    Berte' R; Mazza S; Stefanucci MR; Noviello D; Costa S; Ciafardini C; Mileti E; Mapelli M; Pasqualato S; Pinto S; Favale A; Vecchi M; Neurath MF; Atreya R; Fantini MC; Facciotti F; Caprioli F
    J Crohns Colitis; 2021 May; 15(5):864-868. PubMed ID: 33211810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 Igg seroprevalence in IBD patients treated with biologics: first vs. second pandemic wave in a prospective study.
    Mossa M; Neri B; Montesano L; Salvatori S; Marafini I; Scucchi L; Lolli E; Massoud R; Petruzziello C; Bernardini S; Calabrese E; Monteleone G; Biancone L
    Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3787-3796. PubMed ID: 35647861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
    J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies.
    Shehab M; Alrashed F; Alfadhli A; Alotaibi K; Alsahli A; Mohammad H; Cherian P; Al-Khairi I; Alphonse Thanaraj T; Channanath A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960217
    [No Abstract]   [Full Text] [Related]  

  • 47. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.
    Jackson-Thompson BM; Goguet E; Laing ED; Olsen CH; Pollett S; Hollis-Perry KM; Maiolatesi SE; Illinik L; Ramsey KF; Reyes AE; Alcorta Y; Wong MA; Davies J; Ortega O; Parmelee E; Lindrose AR; Moser M; Graydon E; Letizia AG; Duplessis CA; Ganesan A; Pratt KP; Malloy AM; Scott DW; Anderson SK; Snow AL; Dalgard CL; Powers JH; Tribble D; Burgess TH; Broder CC; Mitre E
    BMC Infect Dis; 2021 Jun; 21(1):544. PubMed ID: 34107889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.
    Zhang X; Lu S; Li H; Wang Y; Lu Z; Liu Z; Lai Q; Ji Y; Huang X; Li Y; Sun J; Wu Y; Xu X; Hou J
    Virol Sin; 2020 Dec; 35(6):820-829. PubMed ID: 33351168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
    Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
    Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs.
    Martínez-Domínguez SJ; García-Mateo S; Sainz-Arnal P; Martínez-García J; Gallego-Llera B; Lozano-Limones MJ; Hidalgo S; Gargallo-Puyuelo CJ; Latre-Santos M; Nocito-Colon MML; Martínez-Lostao L; Refaie E; Arroyo-Villarino MT; Del Rio-Nechaevsky M; Ramirez-Labrada A; Pardo J; Gomollón F; Baptista PM
    Sci Rep; 2023 Dec; 13(1):23061. PubMed ID: 38155275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
    Pijls PA; Gilissen LP
    Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serological response to vaccination against coronavirus disease-19 in patients with inflammatory bowel disease.
    Mathur A; Sahu S; Rai S; Ghoshal U; Ghoshal UC
    Indian J Gastroenterol; 2023 Feb; 42(1):64-69. PubMed ID: 36598745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.
    Moses J; Alkhouri N; Shannon A; Raig K; Lopez R; Danziger-Isakov L; Feldstein AE; Zein NN; Wyllie R; Carter-Kent C
    Am J Gastroenterol; 2012 Jan; 107(1):133-8. PubMed ID: 21876562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
    Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK).
    Talaei M; Faustini S; Holt H; Jolliffe DA; Vivaldi G; Greenig M; Perdek N; Maltby S; Bigogno CM; Symons J; Davies GA; Lyons RA; Griffiths CJ; Kee F; Sheikh A; Richter AG; Shaheen SO; Martineau AR
    BMC Med; 2022 Feb; 20(1):87. PubMed ID: 35189888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
    Helwig U; Braegger F; Kostev K; Schmidt C
    Dig Dis; 2020; 38(6):466-473. PubMed ID: 32045927
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.
    Beigel F; Deml M; Schnitzler F; Breiteneicher S; Göke B; Ochsenkühn T; Brand S
    PLoS One; 2014; 9(6):e99293. PubMed ID: 24932476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.